The present invention relates to compounds of formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

##STR00001##

The present invention relates to compounds of formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

##STR00001##

Provided herein, in some embodiments, are methods and compositions for the treatment of Charcot-Marie-Tooth disease.

Provided herein, in some embodiments, are methods and compositions for the treatment of Charcot-Marie-Tooth disease.

The present invention is related to new pyrrole derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to pyrrole derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

The present invention is related to new pyrrole derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to pyrrole derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

One aspect of the invention refers to an oral pharmaceutical composition comprising the MDM2-antagonist of formula I

##STR00001##

in a dose range of 30 mg to 45 mg for use in the treatment of cancer, wherein this oral pharmaceutical composition is administered in a treatment cycle of once every three weeks (D1 q3w), wherein this treatment cycle of once every three weeks (D1 q3w) may be repeated that many times as considered beneficial for the patient from a medical point of view.

Another aspect of the invention refers to an MDM2-antagonist of formula I for use in the first line systemic treatment (primary treatment) of dedifferentiated liposarcoma.

A further aspect of the invention refers to the use of the MDM2-antagonist of formula I for the manufacture of a medicament for the treatment of a p53-wildtype and non-MDM2-amplified form of cancer.

One aspect of the invention refers to an oral pharmaceutical composition comprising the MDM2-antagonist of formula I

##STR00001##

in a dose range of 30 mg to 45 mg for use in the treatment of cancer, wherein this oral pharmaceutical composition is administered in a treatment cycle of once every three weeks (D1 q3w), wherein this treatment cycle of once every three weeks (D1 q3w) may be repeated that many times as considered beneficial for the patient from a medical point of view.

Another aspect of the invention refers to an MDM2-antagonist of formula I for use in the first line systemic treatment (primary treatment) of dedifferentiated liposarcoma.

A further aspect of the invention refers to the use of the MDM2-antagonist of formula I for the manufacture of a medicament for the treatment of a p53-wildtype and non-MDM2-amplified form of cancer.

One aspect of the invention refers to an oral pharmaceutical composition comprising the MDM2-antagonist of formula I

##STR00001##

in a dose range of 30 mg to 45 mg for use in the treatment of cancer, wherein this oral pharmaceutical composition is administered in a treatment cycle of once every three weeks (D1 q3w), wherein this treatment cycle of once every three weeks (D1 q3w) may be repeated that many times as considered beneficial for the patient from a medical point of view.

Another aspect of the invention refers to an MDM2-antagonist of formula I for use in the first line systemic treatment (primary treatment) of dedifferentiated liposarcoma.

A further aspect of the invention refers to the use of the MDM2-antagonist of formula I for the manufacture of a medicament for the treatment of a p53-wildtype and non-MDM2-amplified form of cancer.

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. ##STR00001##